Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts
Version of Record online: 3 JUL 2011
© 2011 Japanese Cancer Association
Volume 102, Issue 8, pages 1545–1552, August 2011
How to Cite
Naganuma, Y., Choijamts, B., Shirota, K., Nakajima, K., Ogata, S., Miyamoto, S., Kawarabayashi, T. and Emoto, M. (2011), Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Science, 102: 1545–1552. doi: 10.1111/j.1349-7006.2011.01998.x
- Issue online: 18 JUL 2011
- Version of Record online: 3 JUL 2011
- Accepted manuscript online: 1 JUN 2011 02:43PM EST
- (Received February 15, 2011/Revised May 6, 2011/Accepted May 10, 2011/Accepted manuscript online June 1, 2011/Article first published online July 4, 2011)
Fig. S1. Illustration showing the in vitro angiogenesis model.
Fig. S2. Immunoexpression of TP and VEGF in primary carcinosarcoma.
Fig. S3. Human TSP-1 gene expression in HUVEC (A) and FU-MMT-1 cells (B).
Fig. S4. Results of the cytotoxicity assay in HUVEC.
Fig. S5. Changes in sonographic vascular density at week 8.
Fig. S6. Anti-angiogenic effects determined by LDPI.
Table S1. Laser Doppler flowmeter analysis of FU-MMT-1 xenografts at week 4 of treatment.
Data S1.In vitro tube formation assay; assessment of human TSP-1 gene expression in FU-MMT-1 cells and HUVEC; cytotoxicity assay; contrast-enhanced color Doppler US; laser Doppler perfusion imaging; and western blot analysis.
|CAS_1998_sm_DataS1.doc||36K||Supporting info item|
|CAS_1998_sm_fS1.tif||240K||Supporting info item|
|CAS_1998_sm_fS3B.tif||178K||Supporting info item|
|CAS_1998_sm_fS4.tif||205K||Supporting info item|
|CAS_1998_sm_fS5A-D.tif||2056K||Supporting info item|
|CAS_1998_sm_fS5E.tif||213K||Supporting info item|
|CAS_1998_sm_fS6A-F.tif||3526K||Supporting info item|
|CAS_1998_sm_fS2A-D.tif||3875K||Supporting info item|
|CAS_1998_sm_fS3A.tif||228K||Supporting info item|
|CAS_1998_sm_tS1.xls||22K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.